C-Peptide Longevity-Medicine Target Ranges: What Optimal Levels Actually Mean

What Is C-Peptide and Why Does It Matter for Longevity?

C-peptide (connecting peptide) is a 31-amino-acid fragment cleaved from proinsulin in equal molar amounts with insulin inside pancreatic beta cells. Every pulse of insulin secretion releases an identical number of C-peptide molecules. Because the liver clears very little C-peptide on first pass (roughly 10 to 15% vs. Roughly 50 to 60% of insulin), peripheral C-peptide levels reflect pancreatic output more faithfully than insulin itself. [1]

The peptide also has independent biological activity. Research published in the American Journal of Physiology demonstrated that C-peptide binds a G-protein-coupled receptor on endothelial cells, stimulates nitric-oxide synthase, and may protect against diabetic microvascular damage. [2] That finding shifts C-peptide from a passive biomarker to a molecule with direct physiological significance.

Why Standard Reference Ranges Are Not Enough

Laboratory reference intervals are constructed to exclude roughly 95% of an apparently healthy population. That definition captures disease states at both extremes. For longevity medicine, the question is narrower: at what fasting C-peptide level is beta-cell demand minimized, insulin resistance low, and cardiometabolic risk reduced? The answer sits inside the standard range, not at its boundaries.

C-Peptide vs. Fasting Insulin: Which to Order?

Fasting insulin is more widely ordered but suffers from hepatic extraction variability and significant inter-assay coefficient of variation (often 20 to 30%). C-peptide assays are more standardized, and the World Health Organization has maintained an international reference reagent since 1984. [3] When both are available, the ratio of C-peptide to insulin (C:I ratio) can detect early hepatic insulin resistance, a C:I molar ratio below 5 suggests reduced hepatic insulin clearance. [4]

Standard Laboratory Reference Ranges

Most US clinical laboratories report fasting C-peptide between 0.8 and 3.85 ng/mL (SI: approximately 0.26 to 1.27 nmol/L). The conversion factor is 1 ng/mL = 0.33 nmol/L. Post-stimulation values (2-hour oral glucose tolerance test or mixed-meal tolerance test) typically peak at 2.0 to 5.0 ng/mL in metabolically healthy adults. [5]

Age and Sex Adjustments

C-peptide rises modestly with age in cross-sectional studies, likely because age-related insulin resistance demands greater beta-cell output. A 2019 analysis of NHANES data (N = 4,214) found that adults aged 60 to 74 had fasting C-peptide values roughly 18% higher than adults aged 20 to 39, even after adjustment for BMI. [6] This age-related elevation is not benign. Epidemiological data link it to cardiovascular disease and all-cause mortality (see below).

Sex differences are modest at lean BMI. Postmenopausal women without hormone therapy show higher fasting C-peptide than premenopausal controls, consistent with declining estrogen's effect on insulin sensitivity. Testosterone deficiency in men similarly associates with elevated fasting C-peptide, an important consideration when ordering labs alongside TRT evaluations.

Units and Inter-Lab Variation

Some laboratories report in pmol/L. The conversion is 1 ng/mL = 331 pmol/L. Request the specific assay platform from your lab. Radioimmunoassay (RIA) and electrochemiluminescence immunoassay (ECLIA) platforms can differ by up to 15% for the same sample, a clinically meaningful gap when the target window is only 1.0 ng/mL wide.

Longevity-Medicine Optimal Range

The longevity-medicine optimal fasting C-peptide target of 1.0 to 2.0 ng/mL is derived from convergent lines of evidence: prospective cardiovascular outcome data, cancer epidemiology, and mechanistic studies of insulin-IGF-1 crosstalk. No single randomized trial has tested "titrate C-peptide to 1.0 to 2.0 ng/mL and measure mortality," so this target is a synthesis, not an FDA-cleared guideline. The clinical rationale is outlined below.

Cardiovascular Risk Data

A prospective analysis from the Women's Health Initiative (N = 15,330 postmenopausal women without baseline diabetes) found that participants in the highest quartile of fasting C-peptide (>3.2 ng/mL) faced a 2.7-fold higher risk of incident cardiovascular disease compared to the lowest quartile, even after controlling for BMI, blood pressure, and LDL cholesterol. [7] The association persisted after excluding women who developed diabetes during follow-up, suggesting C-peptide carries cardiovascular information beyond glucose status.

A separate analysis in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (N = 27,548) linked fasting C-peptide above 2.5 ng/mL to a hazard ratio of 1.9 (95% CI 1.4 to 2.6) for cardiovascular mortality in men and women combined. [8]

Cancer and IGF-1 Signaling

Chronic insulin hypersecretion (reflected by elevated C-peptide) amplifies IGF-1 receptor signaling in epithelial tissues. A 2021 meta-analysis in Diabetologia (22 prospective studies, N > 200,000 participants) found that each 1 ng/mL increment in fasting C-peptide was associated with a 17% higher risk of colorectal cancer (RR 1.17, 95% CI 1.09 to 1.26). [9] The mechanism likely involves insulin's mitogenic effects through the IGF-1 receptor on colonocytes. Breast cancer data show a similar but weaker signal (RR approximately 1.09 per 1 ng/mL increment).

Low C-Peptide Risk: The Other End

Values persistently below 0.5 ng/mL fasting in a non-T1D patient may indicate beta-cell exhaustion from long-standing T2D, pancreatic exocrine disease, or prior pancreatitis. The DCCT/EDIC study demonstrated that residual C-peptide secretion (>0.2 pmol/mL by stimulated testing) in T1D patients was associated with significantly lower rates of severe hypoglycemia and better HbA1c trajectories over 18 years of follow-up. [10] Beta-cell reserve, even minimal, has clinical value.

The HealthRX metabolic assessment framework uses a three-zone model for fasting C-peptide:

| Zone | Fasting C-Peptide | Clinical Interpretation | |------|--------------------|-------------------------| | Suboptimal Low | <0.8 ng/mL | Possible beta-cell insufficiency; evaluate for T1D, latent autoimmune diabetes in adults (LADA), or pancreatic disease | | Longevity Optimal | 1.0 to 2.0 ng/mL | Adequate beta-cell reserve with low insulin-excess driven CVD and cancer signal | | Suboptimal High | >2.5 ng/mL fasting | Compensatory hypersecretion; insulin resistance likely; elevated CVD and cancer risk |

Values between 0.8 to 1.0 ng/mL represent a gray zone requiring clinical context (lean BMI, no symptoms, stable glucose: likely acceptable; rising HbA1c: warrants further testing).

Distinguishing Type 1 from Type 2 Diabetes

C-peptide testing is a standard diagnostic tool for diabetes classification. The American Diabetes Association (ADA) 2024 Standards of Care state: "A low or undetectable C-peptide level, particularly in the setting of hyperglycemia, confirms absolute insulin deficiency consistent with type 1 diabetes." [11]

Practical Diagnostic Thresholds

• C-peptide <0.2 ng/mL (fasting or stimulated) with glucose >216 mg/dL strongly suggests T1D or absolute deficiency.
• C-peptide 0.2 to 0.6 ng/mL (stimulated) represents partial preservation, common in LADA, late T1D, or long-standing T2D.
• C-peptide >0.6 ng/mL (stimulated) indicates meaningful beta-cell reserve; T2D, monogenic diabetes, or other non-autoimmune etiology more likely.

The T1D Exchange Clinic Network registry (N = 25,880) found median stimulated C-peptide of 0.01 nmol/L (<0.03 ng/mL) in adults with T1D duration >3 years, confirming near-complete beta-cell loss in established T1D. [12]

LADA: The Missed Diagnosis

Latent autoimmune diabetes in adults (LADA) is misclassified as T2D in an estimated 2 to 12% of adults initially presenting with non-insulin-dependent diabetes. LADA patients typically have fasting C-peptide between 0.3 and 1.5 ng/mL at diagnosis with positive islet autoantibodies (GAD65, IA-2). C-peptide measured 3 years after diagnosis in the UKPDS LADA sub-cohort showed a decline rate three times faster than matched T2D controls, an early detection window that changes management.

C-Peptide in the Context of Hormone Therapy

Testosterone Replacement Therapy (TRT)

Hypogonadal men have elevated fasting insulin and C-peptide compared to age-matched eugonadal controls. A randomized controlled trial published in Diabetes Care (N = 220, 52 weeks) found that testosterone undecanoate 1,000 mg IM every 12 weeks reduced fasting C-peptide by a mean of 0.38 ng/mL compared to placebo in men with hypogonadism and T2D, consistent with improved insulin sensitivity. [13] Ordering C-peptide at baseline and at 6 months of TRT provides a direct measure of beta-cell demand reduction.

Menopause and HRT

Surgical or natural menopause accelerates insulin resistance. Data from the KEEPS trial (Kronos Early Estrogen Prevention Study, N = 727) showed that oral conjugated equine estrogen 0.45 mg/day increased fasting insulin and C-peptide modestly (+0.19 ng/mL at 48 months), while transdermal estradiol 50 mcg/day had a neutral effect on C-peptide. [14] Route of administration matters because oral estrogens undergo hepatic first-pass metabolism, blunting hepatic insulin clearance and raising peripheral C-peptide. Transdermal estradiol is generally preferred from a metabolic standpoint, a position consistent with the Menopause Society's 2023 position statement on cardiovascular risk. [15]

GLP-1 Receptor Agonists and Dual Agonists

GLP-1 receptor agonists reduce fasting C-peptide by improving insulin sensitivity, not by directly suppressing beta-cell function. In STEP-1 (N = 1,961), semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo (P<0.001). [16] The accompanying metabolic substudy showed mean fasting C-peptide fell from 2.84 ng/mL at baseline to 2.21 ng/mL at 68 weeks in the semaglutide arm, a 22% reduction tracking the degree of insulin-resistance reversal. Similarly, tirzepatide 15 mg in SURMOUNT-1 (N = 2,539) produced 20.9% weight loss and a 28% reduction in HOMA-B (beta-cell demand index) at 72 weeks. [17]

Patients using GLP-1 therapy should have C-peptide reassessed at 3 to 6 months. A fasting C-peptide already at or below 1.0 ng/mL before GLP-1 initiation warrants caution about dose escalation because hypoglycemia risk rises as insulin secretion capacity is already limited.

How to Test: Protocol and Pre-Analytic Variables

Correct specimen collection significantly affects C-peptide results. The following protocol minimizes pre-analytic error.

Fasting Protocol

• Fast for 8 to 12 hours (water is permitted).
• Avoid vigorous exercise for 24 hours before the draw (acute exercise can transiently raise C-peptide by up to 15%).
• Collect in a chilled EDTA or SST tube and centrifuge within 30 minutes; C-peptide is stable in serum for 24 hours at 4°C, or indefinitely if frozen at -20°C.

Stimulated Testing

A 75 g oral glucose tolerance test (OGTT) with C-peptide drawn at 0, 60, and 120 minutes provides a dynamic picture of beta-cell reserve. The mixed-meal tolerance test (MMTT) using Boost or Ensure (480 kcal, 6 mL/kg to a max of 360 mL) is the preferred stimulation method in T1D research per the JDRF protocol, with C-peptide at 0, 15, 30, 60, 90, and 120 minutes.

Confounders to Report to Your Clinician

Exogenous insulin use does not cross-react with C-peptide assays, making C-peptide valid even in insulin-treated patients, a key advantage. Renal impairment raises C-peptide because the kidney clears roughly 50% of circulating C-peptide. A GFR below 30 mL/min/1.73 m² may raise C-peptide by 30 to 50% independent of beta-cell activity; always interpret in the context of a concurrent creatinine or eGFR.

Acting on Results: Clinical Decision Pathways

C-Peptide >2.5 ng/mL Fasting

Order a full insulin-resistance panel: fasting insulin, HOMA-IR (calculated as fasting glucose [mg/dL] × fasting insulin [µIU/mL] / 405), HbA1c, and a lipid panel with triglycerides. A triglyceride-to-HDL ratio above 3.0 alongside elevated C-peptide is a strong phenotypic marker of small, dense LDL and atherogenic dyslipidemia. Dietary carbohydrate reduction, aerobic exercise (150+ minutes per week of moderate intensity per AHA guidelines [18]), and consideration of GLP-1 therapy or metformin are first-line interventions.

C-Peptide 1.0 to 2.0 ng/mL Fasting

This is the longevity-optimal zone. Annual repeat testing is sufficient unless metabolic status changes (significant weight gain, new medications, new diagnosis). Continue monitoring HbA1c and fasting glucose to confirm glucose-regulatory function matches the C-peptide signal.

C-Peptide <0.8 ng/mL Fasting

Check GAD65 and IA-2 autoantibodies to screen for LADA or T1D. Confirm the result on a repeat fasting draw. If autoantibodies are negative and the patient has normal glucose, consider pancreatic imaging (CT or MRI) if there is clinical suspicion for exocrine disease. An endocrinology referral is appropriate when fasting C-peptide is below 0.5 ng/mL in a previously non-insulin-dependent patient.

Monitoring Frequency in Longevity Medicine Practice

Healthy adults with no diabetes risk factors and a C-peptide in the 1.0 to 2.0 ng/mL range can reasonably retest every 12 to 24 months as part of a comprehensive metabolic panel. Adults on GLP-1 therapy, TRT, or systemic estrogen therapy should recheck at 3 and 6 months after any dose change, then annually once stable. Patients actively losing more than 5% of body weight should retest at each 5% milestone: rapid fat loss alters insulin sensitivity quickly and C-peptide tracks the beta-cell response in near real-time.